These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 37514022

  • 21. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
    Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA.
    Clin Chem Lab Med; 2016 Jul 01; 54(7):1211-9. PubMed ID: 26587745
    [Abstract] [Full Text] [Related]

  • 22. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.
    Rocha C, Lago P, Fernandes S, Correia L, Portela F, Vieira AI, Patita M, Arroja B, Ministro P, Alves C, Dias CC, Magro F.
    Therap Adv Gastroenterol; 2020 Jul 01; 13():1756284820965790. PubMed ID: 33281935
    [Abstract] [Full Text] [Related]

  • 23. Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies.
    Berger AE, Gleizes A, Waeckel L, Roblin X, Krzysiek R, Hacein-Bey-Abina S, Soriano A, Paul S.
    Int J Mol Sci; 2022 Aug 24; 23(17):. PubMed ID: 36076966
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays.
    Vroemen WHM, Agata SS, van Beers JJBC, Damoiseaux JGMC.
    Antibodies (Basel); 2024 Sep 05; 13(3):. PubMed ID: 39311378
    [Abstract] [Full Text] [Related]

  • 25. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, Gils A.
    Ther Drug Monit; 2015 Aug 05; 37(4):479-85. PubMed ID: 25525757
    [Abstract] [Full Text] [Related]

  • 26. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
    Grasmeier MK, Weber S, Treiber M, Thaler MA, Luppa PB.
    Clin Chem Lab Med; 2023 Jun 27; 61(7):1255-1265. PubMed ID: 36753693
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY, Lee Y, Choe BH, Kang B.
    Gut Liver; 2021 Jul 15; 15(4):588-598. PubMed ID: 33024062
    [Abstract] [Full Text] [Related]

  • 29. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation.
    Karsten C, Grannas K, Bergman O, Movérare R, Roforth M, Willrich MAV, Snyder MR, Yang YK.
    AAPS J; 2024 Jul 24; 26(5):86. PubMed ID: 39044059
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease.
    Mc Gettigan N, Afridi AS, Harkin G, Lardner C, Patchett S, Cheriyan D, Harewood G, Boland K, O'Toole A.
    Int J Colorectal Dis; 2021 Jun 24; 36(6):1231-1241. PubMed ID: 33515082
    [Abstract] [Full Text] [Related]

  • 32. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
    Grinman AB, de Souza MDGC, Bouskela E, Carvalho ATP, de Souza HSP.
    Medicine (Baltimore); 2020 Mar 24; 99(10):e19359. PubMed ID: 32150077
    [Abstract] [Full Text] [Related]

  • 33. Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab.
    Cherry M, Dutzer D, Nasser Y, Berger AE, Roblin X, Paul S.
    J Clin Med; 2020 Aug 25; 9(9):. PubMed ID: 32854232
    [Abstract] [Full Text] [Related]

  • 34. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels.
    Pérez I, Fernández L, Sánchez-Ramón S, Alba C, Zatarain A, Cañas M, López ON, Olivares D, Rey E, Taxonera C.
    Therap Adv Gastroenterol; 2018 Aug 25; 11():1756284818783613. PubMed ID: 30034528
    [Abstract] [Full Text] [Related]

  • 35. Comparison of three commercially available ELISA assays for anti-infliximab antibodies.
    West TA, Sam M, Toong C.
    Pathology; 2021 Jun 25; 53(4):508-514. PubMed ID: 33272693
    [Abstract] [Full Text] [Related]

  • 36. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M.
    Intern Med J; 2019 Apr 25; 49(4):513-518. PubMed ID: 30091273
    [Abstract] [Full Text] [Related]

  • 37. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
    Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL.
    Clin Chem; 2020 Oct 01; 66(10):1319-1328. PubMed ID: 32918468
    [Abstract] [Full Text] [Related]

  • 38. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P, Skribanek S, Milassin Á, Farkas K, Bor R, Fábián A, Rutka M, Bálint A, Szántó KJ, Tóth T, Nagy F, Szepes Z, Boda K, Molnár T.
    Orv Hetil; 2020 Nov 22; 161(47):1989-1994. PubMed ID: 33226355
    [Abstract] [Full Text] [Related]

  • 39. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC, Sendecki J, Cornillie F, Popp JW, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G.
    AAPS J; 2017 Jan 22; 19(1):161-171. PubMed ID: 27600137
    [Abstract] [Full Text] [Related]

  • 40. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
    Dave MB, Dherai AJ, Desai DC, Keny BG, Shetty DN, Kulkarni S, Peddy K, Ashavaid TF.
    Indian J Gastroenterol; 2020 Oct 22; 39(5):426-434. PubMed ID: 33118097
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.